| 000 | 03178naa a22005057i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-064 | ||
| 003 | local | ||
| 005 | 20261005174906.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2022 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1186/s12943-022-01663-0 _2doi |
|
| 035 | _a(local)EuropePMC:PMC9547409 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aJunru Lu _eauthor. |
|
| 245 | 1 | 4 |
_aThe journey of CAR-T therapy in hematological malignancies. / _cJunru Lu; Guan Jiang. |
| 264 | 1 |
_a[Place of publication not identified] : _bBMC, _c2022. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aChimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products, such as Kymriah, Yescarta and Tecartus, have been developed and got the unprecedented results. However, some patients may relapse afterwards, driving intense investigations into promoting the development of novel strategies to overcome resistance and mechanisms of relapse. Notable technical progress, such as nanobodies and CRISPR-Case9, has also taken place to ensure CAR-T cell therapy fully satisfies its medical potential. In this review, we outline the basic principles for the development and manufacturing processes of CAR-T cell therapy, summarize the similarities and differences in efficacy of different products as well as their corresponding clinical results, and discuss CAR-T immunotherapy combined with other clinical effects of drug therapy. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aHematological malignancies | |
| 650 | 4 | _aTargeted Therapy | |
| 650 | 4 | _aCombinatorial Therapy | |
| 650 | 4 | _aDrug Product | |
| 650 | 4 | _aCar-t Cell Therapy | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahematology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aGuan Jiang _eauthor. |
|
| 773 | 0 |
_tMolecular cancer _gVol. 21, no. 1, (2022), pages/article 194 _x1476-4598 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC9547409 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC9547409 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1206 _d1206 |
||